我国医保药品支付标准建设的理论与现实分析

发布时间：2018-04-22 14:18

本文选题：药品 + 医保药品支付标准　；参考：《中国卫生政策研究》2017年11期

【摘要】：建立针对药品的医疗保险支付标准(参考价)是多国控制药品费用不合理增长的重要措施。医保药品支付标准通过药品价格竞争刺激患者需求和增强患者选择的权利来影响医生行为和药品企业定价。我国放开药品政府定价后也亟需建立适应药品市场发展的价格形成机制,建立医保药品支付标准需要从我国药品管理政策转变和现状出发,厘清控费的具体机制,根据当前我国实践中存在的问题,从药物经济学评价、药品分级分类管理、完善医保药品支付方式和补偿机制、合理分配补偿结余等方面入手,提升药品的可及性、费用的可控性和政策的激励性。
[Abstract]:Establishing the standard of medical insurance payment for drugs (reference price) is an important measure to control the unreasonable increase of drug cost in many countries. The standard of health care drug payment affects the behavior of doctors and the pricing of drug companies by stimulating patients' demand and enhancing patients' right to choose by means of drug price competition. After our country liberalizes the drug government pricing, it is urgent to establish the price forming mechanism that adapts to the development of the drug market. To establish the medical insurance drug payment standard, we need to clarify the specific mechanism of the control fee from the transformation and the present situation of the drug management policy in our country. According to the problems existing in the practice of our country at present, starting with the aspects of the evaluation of pharmacoeconomics, the classification and management of drugs, the improvement of the payment mode and compensation mechanism of medical insurance drugs, the rational distribution of compensation balance, and so on, the availability of drugs can be improved. Cost control and policy incentives.
【作者单位】：湖北经济学院财政与公共管理学院;
【基金】：湖北省教育厅人文社会科学研究项目(17Q142)
【分类号】：R95

【相似文献】